Prevention of progression in Parkinson's disease

Biometals : an International Journal on the Role of Metal Ions in Biology, Biochemistry, and Medicine
Jan AasethPer M Roos

Abstract

Environmental influences affecting genetically susceptible individuals seem to contribute significantly to the development of Parkinson's disease (PD). Xenobiotic exposure including transitional metal deposition into vulnerable CNS regions appears to interact with PD genes. Such exposure together with mitochondrial dysfunction evokes a destructive cascade of biochemical events, including oxidative stress and degeneration of the sensitive dopamine (DA) production system in the basal ganglia. Recent research indicates that the substantia nigra degeneration can be decelerated by treatment with iron binding compounds such as deferiprone. Interestingly compounds known to decrease PD risk including caffeine, niacin, nicotine and salbutamol also possess iron binding properties. Adequate function of antioxidative mechanisms in the vulnerable brain cells can be restored by acetylcysteine supplementation to normalize intracellular glutathione activity. Other preventive measures to reduce deterioration of dopaminergic neurons may involve life-style changes such as intake of natural antioxidants and physical exercise. Further research is recommended to identify therapeutic targets of the proposed interventions, in particular protection of ...Continue Reading

References

Jan 1, 1990·Free Radical Research Communications·S A Hamburger, P B McCay
Nov 1, 1990·The Journal of Clinical Investigation·T P KennedyJ R Hoidal
Feb 9, 1973·Science·J T RotruckW G Hoekstra
Jan 1, 1983·Annual Review of Biochemistry·A Meister, M E Anderson
Apr 1, 1984·Environmental Health Perspectives·J S Bus, J E Gibson
Feb 1, 1984·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·J W Langston, P Ballard
Jan 1, 1997·Journal of Neural Transmission·R K PearceC D Marsden
Apr 29, 1999·Journal of Neuroscience Research·A H StokesK E Vrana
May 20, 2000·JAMA : the Journal of the American Medical Association·G W RossL R White
Jul 9, 2003·Annals of the New York Academy of Sciences·P TeismannS Przedborski
Aug 20, 2003·Archives of Neurology·Honglei ChenAlberto Ascherio
Sep 16, 2003·Neuron·William Dauer, Serge Przedborski
Aug 28, 2004·Trends in Neurosciences·Maryka Quik
Mar 26, 2005·Brain Research. Molecular Brain Research·Richard Jay Smeyne, Vernice Jackson-Lewis
Oct 28, 2005·Brain : a Journal of Neurology·Daniela BergThomas Gasser
Apr 22, 2006·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Jie ZhangBao-Lu Zhao
Jun 29, 2007·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Jun PengJulie K Andersen
Nov 7, 2007·Neurology·Angelika D WahnerBeate Ritz
Jan 9, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Victoria A GoodwinJohn L Campbell
Mar 18, 2008·Current Opinion in Chemical Biology·Kevin J Barnham, Ashley I Bush
Jun 7, 2008·Archives of Physical Medicine and Rehabilitation·Beth E FisherGiselle Petzinger
Aug 12, 2008·Current Drug Safety·Mahyar Etminan, Samy Suissa
Aug 16, 2008·The European Journal of Neuroscience·D W AndersonJ S Schneider
Jan 17, 2009·Neuroscience Letters·Jeff BlackintonMark R Cookson
Apr 29, 2009·Journal of Trace Elements in Medicine and Biology : Organ of the Society for Minerals and Trace Elements (GMS)·Dag G EllingsenJan Aaseth
Jul 3, 2009·Journal of the American College of Nutrition·José Luis Barranco QuintanaRafael Fernández-Crehuet Navajas
Dec 17, 2009·Neuromolecular Medicine·Roberto G LucchiniBrent C Doney
Feb 26, 2010·Journal of Alzheimer's Disease : JAD·João CostaAntónio Vaz-Carneiro
Mar 24, 2010·Neurology·Joshua J Gagne, Melinda C Power
Apr 24, 2010·Psychopharmacology·Stephen J HeishmanEdward G Singleton
Jun 15, 2010·Progress in Neurobiology·K L DoubleG M Halliday

❮ Previous
Next ❯

Citations

Sep 27, 2019·CNS Drugs·Niels BergslandRobert Zivadinov
Oct 28, 2019·Nursing·Vincent M Vacca
Nov 23, 2019·International Journal of Molecular Sciences·Rita Moretti, Costanza Peinkhofer
Sep 11, 2020·Environmental Science and Pollution Research International·Siju Ellickal NarayananBijo Mathew
Mar 15, 2020·Biometals : an International Journal on the Role of Metal Ions in Biology, Biochemistry, and Medicine·Emma LorentzonPernilla Wittung-Stafshede
Mar 1, 2019·International Journal of Molecular Sciences·Valeria GasperiMaria Valeria Catani
Feb 23, 2020·Frontiers in Neurology·Min WangChanglian Tan
Feb 23, 2020·International Journal of Environmental Research and Public Health·Jan AasethGeir Bjørklund
Aug 23, 2020·International Journal of Molecular Sciences·B MahalakshmiV Bharath Kumar
Jan 26, 2020·Life Sciences·Ya-Shuo FengFeng Zhang
Feb 14, 2021·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·E I GusevM V Ugryumov
Feb 19, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Sachchida Nand RaiM P Singh
Jul 12, 2020·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Geir BjørklundMichael Maes
Aug 21, 2021·Critical Reviews in Biotechnology·Mohan Prasad SinghNarsingh Bahadur Singh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Basal ganglia in Parkinson's disease (MDS)

The basal ganglia is comprised of the neostriatum, the external and internal pallidal segments, the subthalamic nucleus, the substantia nigra pars reticulata, and the pars compacta of the substantia nigra. The basal ganglia circuitry is responsible for the correct execution of voluntary movements and is implicated in Parkinson's disease. Here is the latest research investigating the basal ganglia in Parkinson's disease.